Registration enables users to use special features of this website, such as past
order histories, retained contact details for faster checkout, review submissions, and special promotions.
Registration enables users to use special features of this website, such as past
order histories, retained contact details for faster checkout, review submissions, and special promotions.
Registration enables users to use special features of this website, such as past
order histories, retained contact details for faster checkout, review submissions, and special promotions.
Registration enables users to use special features of this website, such as past
order histories, retained contact details for faster checkout, review submissions, and special promotions.
PathPlusTM ER Alpha / Estrogen Receptor Antibodies
ER (Estrogen receptor / ESR1) is a biomarker that is prognostic for breast cancer and predicts response to hormonal therapy. Estrogen receptor is a nuclear hormone receptor with nuclear staining in malignant breast cancer cells, and usually has higher levels of expression in Luminal A subtypes compared to others (Jeselsohn, 2015). Levels of expression of estrogen receptor are used in conjunction with progesterone receptor (PR), HER2 and Ki-67 expression levels to subtype breast cancers for different downstream treatments. Most breast cancers have positive expression of ER protein, primarily in luminal tissues where the luminal A subtype sees high levels of expression. Staining for this target is expected to be nuclear.
References: Nature reviews. Clinical oncology 2015 Jan; 12.1; 573-583, PMID: 26122181; World Journal of Clinical Oncology 2014 Aug; 5.3; 412-424, PMID:25114856;